Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||HER2-pulsed DC1 vaccine|
HER2-pulsed DC1 vaccine is a cancer vaccine comprising patient-derived dendritic cells exposed to ERBB2 (HER2)-derived peptides, which potentially enhances anti-tumor immune response against ERBB2 (HER2)-expressing tumor cells (NCI Drug Dictionary).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|HER2-pulsed DC1 vaccine||HER2-pulsed type-1 polarized autologous dendritic cell vaccine||HER2 (ERBB2) Vaccine 12||HER2-pulsed DC1 vaccine is a cancer vaccine comprising patient-derived dendritic cells exposed to ERBB2 (HER2)-derived peptides, which potentially enhances anti-tumor immune response against ERBB2 (HER2)-expressing tumor cells (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03630809||Phase II||HER2-pulsed DC1 vaccine||Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1||Terminated||USA||0|
|NCT05378464||Phase I||Pepinemab + Trastuzumab HER2-pulsed DC1 vaccine||Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer||Recruiting||USA||0|
|NCT03384914||Phase II||HER2-pulsed DC1 vaccine pUMVC3-IGFBP2-HER2-IGF1R vaccine||Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer||Recruiting||USA||0|
|NCT02063724||Phase I||HER2-pulsed DC1 vaccine||HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer (Adjuvant)||Active, not recruiting||USA||0|
|NCT02336984||Phase Ib/II||Trastuzumab HER2-pulsed DC1 vaccine||A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS||Withdrawn||USA||0|
|NCT02061332||Phase Ib/II||HER2-pulsed DC1 vaccine||DC Vaccine for Patients With Ductal Carcinoma In Situ||Completed||USA||0|
|NCT03387553||Phase I||HER2-pulsed DC1 vaccine||HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer||Recruiting||USA||0|